Wolff Parkinson White syndrome in pregnant patient

Abstract

Introduction: Pregnancy is a physiological state of several anatomical, hormonal, hemodynamic and
electrophysiological changes. Wolff-Parkinson-White syndrome is a congenital abnormality in the electrical
conduction system of the heart, with suggestive changes in pre-excitation in the electrocardiogram, WHO
targets in reducing neonatal maternal morbidity.

Objective: Describe the clinical case of a pregnant patient with cardiac pathology compatible with Wolff
Parkinson White Syndrome in treatment with beta blocker drug.

Material and methods: Retrospective descriptive study, clinical case presentation.

Results: 17-year-old female sex patient with a history of Wolff Parkinson White Syndrome (WPW) diagnosed
2 years ago 7 months ago in treatment with Carvedilol 6.25mg once daily with regular monitoring with
cardiologist. Attends subsequent pregnancy control (24 weeks gestation) with laboratory test result within
normal parameters, refers to palpitations, accompanied by sweating, asthenia and vertigo of an hour of
evolution for which 6.25 mg of additional carvedilol at the usual dose without improvement. At the time
Score MAMA 3 at the expense of the heart rate (200-220 lpm) so it is transferred with all primary measures to
unit of greater resolution capacity for stabilization and evaluation by cardiologist, which suspends usual
medication and starts Atenolol 50 mg once daily until end of pregnancy, explains possible fetal side effects
and continues with prenatal and pathology-based checks with cardiology.

Conclusions: Scientific evidence on beta blockers and safety during pregnancy remains a source of study and
controversy, so new research will be needed in the coming years to further clarify this aspect.